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Introduction: The World Health Organization recommends vaccination of health workers (HWs) against
influenza, but low uptake is intransigent.
We conducted a Rapid Evidence Appraisal on: the risk of influenza in HWs, transmission risk from HWs
to patients, the benefit of HW vaccination, and strategies for improving uptake. We aimed to capture a
‘whole-of-system’ perspective to consider possible benefits for HWs, employers and patients.
Methods: We executed a comprehensive search of the available literature published from 2006 to 2018 in
the English language. We developed search terms for seven separate questions following the PICO frame-
work (population, intervention, comparators, outcomes) and queried nine databases.
Results: Of 3784 publications identified, 52 met inclusion criteria. Seven addressed HW influenza risk, of
which four found increased risk; 15 addressed influenza vaccine benefit to HWs or their employers, of
which 10 found benefit; 11 addressed influenza transmission from HWs to patients, of which 6 found evi-
dence for transmission; 12 unique studies addressed whether vaccinating HWs produced patient benefit,
of which 9 concluded benefits accrued. Regarding the number of HWs needed to vaccinate (NNV) to deli-
ver patient benefit, NNV estimates ranged from 3 to 36,000 but were in significant disagreement.
Fourteen studies provided insights on strategies to improve uptake; the strongest evidence was for
mandatory vaccination.
Conclusions: The evidence on most questions related to influenza vaccination in HWs is mixed and often
of low-quality. Substantial heterogeneity exists in terms of study designs and settings, making compar-
ison between studies difficult. Notwithstanding these limitations, a majority of studies suggests that
influenza vaccination benefit HWs and their employers; and HWs are implicated in transmission events.
The effects of vaccinating HWs on patient morbidity and mortality may include reductions in all-cause
mortality and influenza-like illness (ILI). Taken together, the evidence suggests that HW vaccination is
an important policy for HWs themselves, their employers, and their patients.
 2019 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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1.1. Background
In 2012, the World Health Organization (WHO) updated its rec-
ommendation on influenza vaccination of health workers (HWs)
concluding that ‘‘HWs are an important priority group for influenza
vaccination, not only to protect the individual and maintain
health-care services during influenza epidemics, but also to reduce
spread of influenza to vulnerable patient groups” [1,2]. The WHO
Global Influenza Strategy (2019–2030) reinforces this position by
supporting countries to ‘‘develop and implement national, seasonal
immunization policies for HWs and other high-risk groups” [3].
In 2017, 96 of the 194 WHO Member States reported having
policies in place for influenza vaccination of HWs [4]. However,
the Member States with such policies are unevenly distributed
across WHO regions. Aside from mitigating seasonal influenza,
influenza vaccine is considered the primary intervention to reduce
mortality and morbidity in a severe pandemic. An efficient pan-
demic response depends largely on how well seasonal vaccine
response to annual epidemics is embedded and implemented [5].
The Review Committee on the Functioning of the International
Health Regulations (2005) in relation to Pandemic (H1N1) 2009 con-
cluded that experience with comprehensive seasonal influenza
programmes would provide valuable preparation in advance of a
major pandemic [6]. In November 2018, the Global Alliance for
Vaccines and Immunization (GAVI) Board requested that the GAVI
secretariat in collaboration with WHO assess the feasibility and
impact of routine influenza immunization of HWs to support epi-
demic and pandemic influenza preparedness [7].
To support these global considerations and considering the poor
uptake of influenza vaccination in HWs despite the multiple rea-
sons advocated for it as a policy, we conducted a Rapid Evidence
Appraisal [8]. We aimed to capture the breadth of available evi-
dence on influenza in health care settings and the wider health
impacts of influenza vaccination in HWs. We critically appraised
the literature relating to: influenza risk to HWs and the risk they
pose to their patients; the benefit of influenza vaccination in
HWs; and influenza vaccine uptake in HWs. By including evidence
relevant to multiple stakeholders collectively - HWs, patients, andtheir employers – we holistically evaluated the evidence in the
most policy-relevant framework as possible.
2. Methods
2.1. Systematic literature search
General Search Approach: The search objective was to examine
the evidence under three topics using a Rapid Evidence Appraisal
approach. Each topic gave rise to 2 or 3 questions for query (see
Table 1). Evidence was queried from MEDLINE, EMBASE, CINAHL,
Cochrane CENTRAL, Cochrane Reviews, WHO Global Index Medi-
cus, National Health Service (NHS) Evidence, NHS HTA database,
and multiple international clinical trials’ registries. We executed
three independent searches by topic with distinct search terms
to capture literature for all topic questions. Search terms followed
the PICO framework (population, intervention, comparators, out-
comes) and studies were selected based on pre-determined
criteria.
Study Types varied by review topic and question but generally
included experimental or observational studies, systematic
reviews, controlled observational studies, and randomized con-
trolled trials (RCTs). Due to the volume of evidence for Topic 3
(HW vaccine uptake), literature was restricted to systematic
reviews, RCTs, and evidence-based policy guidelines or toolkits.
Study Outcomes were limited to laboratory-confirmed influenza
as a primary outcome measure, when relevant to the queried ques-
tion. Other outcomes included sickness absence incidence and/or
duration, economic or productivity costs due to illness, influenza-
like- illness (ILI) or respiratory illness, the number needed to vac-
cinate (NNV), and vaccination uptake in HWs.
Study Selection, exclusion and inclusion: Studies were selected
and extracted onto a standardized template by 3 reviewers (DJ,
HM, KM3) independently, defaulting to a third party (JSN-V-T) as
needed. Study selection followed the following process: remove
duplicates and unrelated content by title; review abstracts -
remove unrelated content, descriptive studies, commentaries, or
studies that clearly do not meet the inclusion/exclusion criteria
defined for each question; review full text - exclude based on
exclusion/inclusion criteria or remove studies that lack a clear
Table 1
Rapid Evidence Appraisal topics, queried questions, number of studies selected, and their associated references.
Topic Description Questions Total Studies
cited/
question
Refs.
1 The Impact of HW Influenza
Vaccination on HWs and their
employers
1. What is the evidence that HWs are at an increased risk of influenza infection com-
pared to the general population?
7 [11–17]
2. What is the evidence that vaccinating staff in healthcare settings against influenza
reduces influenza in HWs, absenteeism and/or the wider economic impact of influ-
enza in the healthcare workforce?
14 [11,18–
30]
2 The Impact of HW Influenza
Vaccination on their patients
1. What is the evidence that HWs transmit influenza (asymptomatic or symptomatic) to
inpatients in healthcare settings?
11 [31–41]
2. Does influenza vaccination of HWs provide a protective effect for inpatients in health-
care settings?
6 [11,25,42–
45]
3. If so, what number or proportion of HWs needs to be vaccinated to provide this effect? 8 [11,42,46–
51]
3 Influenza Vaccine Uptake in HWs-
hurdles and solutions
1. What is the evidence for successful practical interventions to increase HW vaccine
uptake of influenza vaccine?
11 [11,25,52–
60]
2. What is the state of knowledge in sociological, behavioural, and public health policy
research on influenza vaccine uptake in HWs?
3 [11,61,62]
D.C. Jenkin et al. / Vaccine: X 2 (2019) 100036 3study design, methodology, or results section. Studies were then
ranked according to the Maryland Scientific Methods (SMS) Quality
Scale [9] with 1 being the lowest and 5 being the highest [10]. We
limited the inclusion of studies to those scoring 2–5 on the quality
scale published from 2006 to 2018 in whole or in summary in the
English language.22.2. Data handling
Data Extraction: Two reviewers (DJ, KM) executed the search
strategy and results were independently screened by three review-
ers (DJ, HM, KM) for eligibility using a three-stage sifting approach
of title, abstract and full-text. The two reviewers for 2006–2016
(DJ, HM) literature reached consensus on which search hits met
the criteria for inclusion at each stage (including exclusion at the
full-text stage). Any disagreements were resolved by discussion
or involvement of an additional reviewer.
Data analysis: Detailed characteristics of included studies were
captured and descriptively summarized in tables and figures iden-
tifying study design, population, setting, measured outcomes,
results, and limitations (See Tables 2–5).3. Literature search results
3.1. Identified literature
The collective literature search identified 3,784 publications, of
which 52 individual publications met the inclusion criteria (see
Fig. 1). Some publications addressed multiple questions resulting
in a total of 60 references cited for all questions combined (see
table 1). Of the 60 included studies, we identified 7 RCTs, 24 obser-
vational studies, 16 reviews (non-systematic or systematic), and 13
‘‘other” study types (see Fig. 2A and B). Individual studies and sys-
tematic reviews were excluded from the final list of included stud-
ies (Tables 2–4) when they formed part of a more recent
systematic review. These removed studies were still considered
in the text if they are of moderate to high quality.2 See supplementary materials for full protocol with search criteria for each topic
and exclusion and inclusion criteria by topic and question. KM executed search
strategy/screened the literature for 2016–2018 and reevaluated inclusion/exclusion
to total search 2006–2018.3.2. Evidence by topic and question (Tables 2–4)
Topic 1 Question 1 - Are HWs at an increased risk of influenza
infection?
We identified only 1 higher quality study (4 or higher score) for
this question. The review by Dini et al. [11] included 28 studies (12
systematic reviews, 13 meta-analyses, 3 appraisals) and addressed
several aspects relevant to influenza vaccination in HWs, including
laboratory-confirmed incidence and risk compared to controls. The
review included a higher level systematic review andmeta-analysis
on the occupational risk of pandemicH1N1 in HWs compared to the
general population or across occupations. This meta-analysis [63]
evaluated 15 studies (29,358 subjects), including 11 high quality
studies of laboratory-confirmed influenza, and showed a signifi-
cantly increased OR = 2.08 (95% CI, 1.73–2.51) in HWswith a higher
risk in physicians {OR = 6.03 (95% CI, 2.11–17.8)}.
Kuster et al. [64], a systematic review also included in Dini et al,
compared data on influenza infection rates in HWs and healthy
adults from 29 surveys (n = 58,245) over 97 influenza seasons
[11]. The review calculated a pooled annual incidence of 18.7%
(95% CI, 15.80–22.11) per season in unvaccinated HWs versus
5.44% (95% CI, 3.01–9.84) per season in unvaccinated adults and
6.49% (95% CI, 4.63–9.09) for vaccinated HWs versus 1.20% (95%
CI, 0.86–1.68) for vaccinated adults. However, this review [64] con-
cluded the overall effect was driven by asymptomatic rather than
symptomatic infections. A German study included as part of Dini
et al evaluated ILI incidence combined with pre and post-season
influenza serology in HWs and non-HWs [65] and concluded there
was no difference in risk of symptomatic or asymptomatic influ-
enza infection in HWs compared to non-HWs [11]. However,
HWs were found to have an increased risk of clinically diagnosed
acute respiratory infection (OR = 3.0, p = 0.04), and were more
likely to have a pre-season antibody titre of  40 to influenza A/
H3N2, indicating the possibility of asymptomatic or subclinical
influenza infections.
Five additional studies of differing methodological approach
and quality provided conflicting conclusions. Three studies pointed
to a higher risk [12,13,16] including a pandemic simulation mod-
elling study [13] which suggested a plausible attack rate as high
as 60% greater in HWs and a moderate-low quality retrospective
study in Hong Kong which suggested a higher H1N1 risk in HWs
and an inconclusive result when applied to seasonal influenza
[12]. Sartor et al. [16] found HWs at an increased risk of influenza
infection in a geriatric hospital, although the study contained fewer
than 50 subjects. A moderate quality case-control study in Canada
Table 2
Rapid Evidence Appraisal included studies and their characteristics for Topic 1 - Questions 1&2.
Study Maryland
Quality
Score and
classification
Study Design Country Setting Included Studies/or Population
type
# of participants Intervention or
Focus
Outcomes Are HWs at a
greater risk than
the general
population Yes/No
Dini [11] 4
High
Moderate
Review Mixed Hospital 2 systematic reviews/ 28
included address this question
29,358 subjects H1N1pdm09
vaccine
Lab-confirmed influenza infection Yes for
H1N1pdm09
Ip [12] 2
Low
Moderate
OS- RC Hong Kong Hospital Inpatient and outpatient health
workers
 6000 H1N1pdm09
risk and impact
All cause or Acute Respiratory Illness
Related Sickness Absenteeism during influenza
epidemics
Yes during 2009
Inconclusive with
seasonal
influenza
Cooley [13] No Score-
Model
Simulation
Pandemic
Simulation
Model
USA Hospital Simulation of influenza
epidemic and the impact on
hospital-based HWs
N/A Seasonal
vaccine
Secondary attack rate of pandemic influenza
among unprotected HWs.
Yes, for pandemic
influenza
Bellei [14] 2
Low
Moderate
OS -PC Brazil -
Outpatients
-
Community
Outpatient health workers,
outpatients with acute
respiratory infection, renal-
transplant patients
203 HWs
140 community
69 renal-
transplant
N/A Lab-confirmed influenza rates by population,
clinical symptoms, and risk factor.
Inconclusive, but
vaccination may
have confounded
results
Yiannakoulias
[15]
3
Moderate
OS-
Retrospective
CC
Canada -Province-
wide
assessment
using
billing data
Medical professionals Exposure to ILI
in a patient
Frequency of exposure to patient with ILI in
7 days prior to ILI diagnosis in case providers vs.
matched control providers
Yes, but can’t
make a clear
connection
between
exposure and ILI
using billing data
Sartor [16] 2
Low
Moderate
OS -PC France Internal
Medicine
Ward
Inpatients and health workers 23 patients and
22 HWs
N/A Attack rate of influenza A among patients and
HWs
Yes, but patients
also at risk
during an
outbreak
Elder [17] 2
Low
Moderate
OS - CS Scotland Acute care
hospitals
Inpatient health workers with
regular patient contact
518 N/A Serologically-confirmed influenza.
Proportion of asymptomatic infection (recall
+ serology)
Yes
for asymptomatic
infection
Imai [18] 5 SR and meta-
analysis
Mixed 13 studies total
3 RCTs, 2PC, 8RC
N = 20,282;
5,083 vaccinated
15,199 not
Seasonal
Vaccine only
Pooled n = RR, Lab-confirmed flu, ILI,
absenteeism, mean difference, cost-
effectiveness
Does vaccine
benefit HWs or
their
employers?
Yes/No
High Yes
Dini [11] 4
High
Moderate
Review Mixed 6 systematic reviews relevant
to this question/ 28 studies
Didn’t pool Influenza
Vaccine
Lab-confirmed flu, ILI, absenteeism Yes
Gianino [20] 2
Low
moderate
OS-RC Italy Hospital Hospital health workers  5000 Seasonal
vaccine
Absenteeism during influenza epidemic periods Yes
Pereira [21] 3
Moderate
OS- RC England 223 health
trusts each
season
Hospital, primary care,
inpatient, outpatient, specialist
800,000 Seasonal
vaccine
Sickness absence rate, Relationship between
sickness absence rate and uptake
Yes
Frederick [25] 3
Moderate
OS-RC USA Hospitals &
Outpatient
Health workers 3000 Mandatory
vaccine policy
Incidence/length of absenteeism mandatory vs.
non-mandatory sites
Yes
4
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Table 2 (continued)
Study Maryland
Quality
Score and
classification
Study Design Country Setting Included Studies/or Population
type
# of participants Intervention or
Focus
Outcomes Does vaccine
benefit HWs or
their employers?
Yes/No
Riphagen-
Dalhuisen
[28]
4
High
Moderate
cRCT The
Netherlands
6 Tertiary
Medical
Centres
All hospital HWs during 2009–
2011
HWs = all from Multi-faceted
uptake
intervention
for
H1N1pdm09
and seasonal
vaccine
Vaccine uptake; absenteeism rates among HWs
in December of each year
No to
absenteeism,
actually saw an
increase
Hui [30] 4
High
Moderate
RCT Malaysia Faculty of
Dentistry
Staff/students of the faculty of
Dentistry Control
.Control = 176
Vaccinated = 179
Seasonal
Vaccine
Follow up over a 4-month period from
vaccination, via questionnaire to ascertain self-
reported outcomes: ILI prevalence; Recurrence
of ILI; Visits to doctor due to ILI; Family
members or housemates reporting ILI, Days of
absenteeism due to ILI, Fever days due to ILI
Yes, to all self-
reported
outcome
measures
Nguyen-
VanTam [23]
2
Low
moderate
OS- RC-TS England Teaching
Hospital,
multiple
wards
HWs – non-medical staff
(nurses/ porters); nursing staff
from admissions, intensive
therapy and surgical; porters
dealing with supplies and
waste
N = 271 N/A Individual sickness absence contrasted
epidemic/ non-epidemic periods in season.
Measured: Total time lost/person as % of
rostered time.# weeks/ person which absence
occurred ‘92-‘93 season non-epidemic yr.
comparison, since low flu activity
No
Atamna [26] 3
Moderate
OS-PC Israel Medical
Centre
Health workers, vaccinated vs.
non-vaccinated during flu
seasons and not
733 vaccinated
908 not (199 in
flu season)
Seasonal
Vaccine
Rates of PCR confirmed influenza A infection in
vaccinated vs. non vaccinated HWs
inconclusive
Njuguna [22] 2
Low
moderate
OS-PC Kenya 5 Hospitals
with
influenza
surveillance
Health Workers who were
offered free vaccine
3803 H1N1pdm09
vaccine
Vaccine effectiveness in vaccinated vs
unvaccinated HCP: Incidence of acute
respiratory illness, absenteeism from work due
to respiratory illness laboratory-confirmed
influenza (using PCR)
No, actually
increased
absenteeism
Saadeh-Navarro
[27]
2
Low
moderate
OS-RC Mexico Teaching
Hospital
Vaccinated HWs (health care
worker defined as all personnel
with patient contact)
N = 3636 Seasonal
influenza
vaccine
A reduction in ILI, Absence due to ILI
Total days of work lost
Yes
Fujita [24] 2
Low
moderate
OS-RC Japan University
hospital
Nursing Staff 1680 Seasonal
vaccine
Vaccine effectiveness through self-reported
fever and cold-like symptoms.
Days absent.
Yes
Preaud [29] No Score
Economic
Model
EM 8 European
Countries
All health
workers for
those
countries
Mixed HWs N/A Seasonal
trivalent
vaccine
Number of influenza-related events averted
(cases, GP visits, hospitalisations, deaths and
days of work lost) at current vaccination
coverage rates.
Yes, to cases
averted
Parlevliet [31] No Score
Cost-
Benefit
Analysis
CBA The
Netherlands
Hospitals Health workers 6251 Seasonal
vaccine
Retrospective cost-benefit model as employer’s
perspective to see costs and benefits. For
vaccine programs as workplace absenteeism.
Yes, To cost
benefit to
employers
LEGEND: CC– Case Controlled; OS- Observational Study; CS- Cross Sectional; PC- Prospective Cohort; RC- Retrospective Cohort; SR-Systematic Review; EM- Economic Model; CBA- Cost-Benefit Analysis; TS- Time Series; RCT-
Randomised Controlled Trial; cRCT- Clustered Randomised Controlled Trial; UC- Unclear; Q1 – Question 1; Q2 – Question 2; RR-Risk Ratio.
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6 D.C. Jenkin et al. / Vaccine: X 2 (2019) 100036found inconclusive results on the risk of ILI in exposed HWs as did
a prospective cohort study in Brazil using lab-confirmed influenza
[14,15].
Topic 1, Question 2 - Does influenza vaccination benefit HWs or
their employers?
We identified several higher quality studies for this question.
Two reviews compared lab-confirmed influenza in vaccinated
HWs vs. controls and found a vaccine efficacy of 50–90% and a
significant protective effect {Relative Risk(RR) = 0.40 (95% CI,
0.23–0.69)} [18,66] for HWs. The high quality systematic review
by Imai et al. [18] further found a reduced incidence of absen-
teeism due to ILI {RR = 0.62 (95%CI, 0.45–0.85)}, and a significantly
shorter sick leave in the vaccinated group {RR = 0.46 (ILI + lab-
confirmed), RR = 0.60 (lab-confirmed)}. The study concluded that
vaccination provided a protective effect in HWs and deemed vacci-
nation programs as cost-saving. The widely-cited studies by Kliner
et al. [66] and Kuster et al. [64] were included in the appraisal by
Dini et al who identified 6 reviews relevant to this question
[64,66–70] and also concluded that vaccination was protective
and potentially cost-saving in HWs [11].
Two contradictory RCTs included a Malaysian study that [28]
found reduced absenteeism (12 days vs. 52 in the control group,
p = 0.002) and ILI (reduced by 52.6%, p = 0.002) due to vaccination,
using all self-reported outcomes. A Dutch RCT [25] actually found
an increase in absenteeism in the vaccinated groups {2009/10
(4.6% vs 3.4%); 2010/11 (4.6% vs 3.9%)}, although they attributed
the increase to more frequent testing for influenza in the interven-
tion cluster and the study was performed during periods of
H1N1pdm09 activity in 2009–2011.
We identified 8 observational studies of moderate to lower
moderate quality [19–23,26,27,30], 5 of which found a vaccine
benefit to HWs or employers and 3 which found no benefift or
inconclusive results. A study in a large Italian hospital found an
increase in absenteeism [19] from 2.99 days/person (outside of
flu season) to 5.06 days/person (during flu season), which trans-
lated to 11,000 attributable absent days/year. The study also found
that vaccinated HWs had fewer excess sick days compared to non-
vaccinated HWs (1.45 days/person vs. 2.09). A retrospective study
in the United States (4063 subjects) compared absenteeism in
mandatory vs. non-mandatory vaccination sites [21] and found
that vaccinated HWs had fewer symptomatic days absent
{2012/2013, OR = 0.82 (95% CI, 0.72–0.93); 2014/2015, OR = 0.81
(95% CI, 0.69–0.95)} and concluded that mandatory vaccination
would reduce symptomatic absenteeism.
Three studies suggested no benefit including a prospective
cohort study in Israel [23] which found HWs less likely to develop
lab-confirmed influenza, although this finding was not significant.
A study in Kenya [26] found vaccinated participants were more
likely to develop acute respiratory illness (ARI) and more likely
to miss work after vaccination. A large retrospective ecological
study [20] evaluated 800,000 HWs per year over 4 flu seasons
in England and found that a 10% increase in vaccine uptake would
lead to a decrease in approximately 0.43 percentage points in the
absolute sickness absence rate (from 4.5% to 4.07%), or a 10% rela-
tive decrease in the sickness rate. Studies looking at the cost-
benefit of vaccination generally found HW vaccination to be cost-
saving and of economic benefit from the perspective of the
employer [18,24,28,29].
Topic 2, Question 1 – Do HWs transmit influenza to patients?
Evidence varied widely in methodological approach, yet some
findings suggest HWs are at least one of the sources of transmis-
sion. We identified moderate to higher quality studies which
implicated HWs in some transmission events, particularly in geri-
atric patients, in acute care settings during flu season [31–33] and
during hospital outbreaks [36]. These studies utilized technologies
such as wearable sensors [31,34], molecular-based subtypingmethods [32], or phylogenetic analyses combined with case stud-
ies or epidemiology [35,40]. One retrospective cohort study ana-
lyzed routes of transmission among HWs and geriatric patients
using molecular-based subtyping methods. The study identified
three nosocomial outbreak clusters within one ‘outbreak’ and
found a higher influenza incidence in patients (24%) than in HWs
(11%) [32]. A large nosocomial outbreak in a geriatric hospital
[35] used detailed case studies combined with phylogenetic analy-
sis to reveal 5 clusters of cases and multiple introductions of com-
munity strains into the hospital. Similarly, a study by Valley-Omar
et al. [40] in South Africa combined epidemiological investigation
with phylogenetic analysis to study influenza transmission chains
and the extent of nosocomial transmission over a four-month per-
iod within a pediatric hospital. This analysis found that most
potential nosocomial infections resulted from multiple introduc-
tions of Influenza A into the hospital and suggested transmission
between asymptomatic patients, HWs, and visitors.
Topic 2, Question 2, Part A – Does influenza vaccination in HWs
benefit patients?
We identified two higher quality studies relevant to this ques-
tion [11,25], and several lower quality studies using ILI [43–45]
as an outcome measure. The comprehensive review by Dini et al.
[11] evaluated 6 systematic reviews [66,69,72–74,76] and found
overall inconclusive results as studies were of moderate but mostly
lower quality, evaluated the same 4 RCTs [77–80], and came to dif-
ferent conclusions. The review included the latest version of a
Cochrane Systematic Review by Thomas et al. [74] which evaluated
these 4 highly cited RCTs in long term care facilities (LTCFs) [77–
80]. However, different from prior reviews by the same author, this
time they excluded all-cause mortality as an outcome measure
(only influenza-related outcomes) and found no conclusive evi-
dence of the benefit of HW vaccination to LTCF residents. They also
found a low quality of evidence with a high risk of bias. Another
systematic review and meta-analysis [76] included in Dini et al
pooled data from 4 RCTs and suggested a benefit to all-cause mor-
tality {RR = 0.71 (95% CI, 0.59 – 0.85)} and ILI {0.58 (95% CI, 0.46 –
0.73)}, but all-cause hospitalization and laboratory-confirmed
influenza were not statistically significantly altered [11].
Although we identified 5 higher quality clustered randomized
controlled trials (cRCTs) [25,77–80] which address this question,
only the Dutch trial [25] was not included in prior reviews (per
our exclusion criteria), other than in de Serres et al. [73] in the next
section, illustrating the need for updated cRCTS. This pragmatic
cRCT [25] measured rates of nosocomial infection as a secondary
outcome in 2 high risk departments – pediatrics and internal med-
icine. Within the higher vaccine coverage groups of the internal
medicine departments, nosocomial influenza and/or pneumonia
was recorded in 3.9% compared to 9.7% in the control hospitals,
respectively (p = 0.015). An increase in vaccine coverage was asso-
ciated with decreased inpatient morbidity from influenza and/or
pneumonia in internal medicine settings, but not in pediatrics.
Topic 2, question 2, Part B - How many HWs need to be vacci-
nated (NNV) to ensure a benefit to patients?
We found a limited number of moderate quality observational
and modelling studies [46–51] which suggest that a proportionate
effect of HW vaccination is likely, where nosocomial influenza
infections decrease with increasing HW vaccination coverage. Sal-
gado et al. [47] conducted a retrospective cross sectional study in a
USA tertiary care hospital over 12 consecutive years. HW vaccina-
tion rates increased from 4% in 1987–1988 to 67% in 1999–2000
(P < 0.0001). Proportions of nosocomial influenza cases among
employees or patients both declined significantly (P < 0.0001).
Logistic regression analysis revealed a significant inverse associa-
tion between HW compliance with vaccination and the rate of
nosocomial influenza among patients (P < 0 0.001). The authors
reported that surveillance of nosocomial spread and isolation poli-
Table 3
Rapid Evidence Appraisal included studies and their characteristics for Topic 2 - Questions 1 – 3.
Study Maryland
Quality
Score and
classification
Study
Design
Country Setting Included Studies/ or
Population type
Intervention or Focus # of participants Outcomes Do HWs transmit influenza to
patients? Yes/No
Voirin [31] 4
High
Moderate
OS-PC France Geriatric
Hospital
Geriatric patients
Nurses, doctors,
contacts in geriatric
setting
Wearable sensors for
12 days
patients (n = 37)
nurses (n = 32),
doctors (n = 15)
contacts
(n = 18,765)
Sensor data combined with lab-
confirmed Influenza A, B,
phylogenetic analyses -track
transmission
Yes
Eibach [32] 3
Moderate
OS-RC France Geriatric
Ward -Acute
Care
Geriatric patients and
HWs tested for flu
Molecular-based
subtyping
Patients (n = 66)
HWs (n = 57)
Nosocomial influenza
transmission confirmed with
molecular and epidemiologic
testing
Yes
Vanhems [33] 3
Moderate
OS-PC France Hosptial in flu
season –
Acute Care
Patients and HWs Exposure- contagious
persons
Patients
(n = 21,519)
HWs (n = 2,153)
RR of hospital-acquired ILI based
on source contacts, lab-
confirmed influenza
Yes
Vanhems [34] 2
Low
Moderate
OS-PC France Geriatric
Ward – Short
Stay
Geriatric Patients,
HWs, contacts
Wearable sensors for
6 days
HWs (n = 46)
Patients (n = 29)
Contacts
(n = 14,037)
Detection of close contact
between HWs, patients, or
contacts combined with time in
contact to measure risk
Suggests yes, but unclear
Pagani [35] 3
Moderate
Outbreak Switzerland Geriatric
Hospital
Suspected cases -
Geriatric patients and
HWs of nosocomial
outbreak
Epidemiology/molecular
typing
N = 155
suspected cases
Respiratory virus molecular
testing and sequencing to
determine nosocomial
transmission patterns
UC, HWs not directly cause
Voirin [36] 3
Moderate
Review mixed Hospital 28 nosocomial
influenza outbreak
reports
n/a; ORION checklist 28 outbreaks Transmission of influenza by
HWs to patients and as index
cases
Yes in 10 studies
Ridgeway [37] 2
Low
Moderate
OS-PC USA University
Hospital
Different types of
healthcare
professionals
Temporary mandatory
flu testing in HWs
HWs (n = 449) % influenza positive HWs by
vaccination status; % influenza
positive symptomatic HWs vs.
asymptomatic
UC, but 50% of flu positives
were
asymptomatic
Kay [38] 2
Low
Moderate
Outbreak USA Hospital
retreat
facility
HWs attendees and
facilitators of a
retreat
Epidemiology/viral
testing
HWs (n = 32)
Facilitators
(n = 14)
Viral load changes and returning
to work, shedding and duration,
the association with symptoms
and fever
UC, but 75% of flu + HWs
returned to work whilst ill
Rodriguez-
Sanchez [39]
2
Low
Moderate
Outbreak
of H1N1
Spain Clinical
Microbiology/
infectious
Diseases Unit
Hospitalized patients
with confirmed H1N1
influenza (HIV + and
non-HIV + )
n/a; genetic sequencing HIV + patients
(n = 49), Non-HIV
+ (n = 37)
Phylogenetic trees, outbreak-
specific substitutions, and viral
variants in infected patients
UC on the source of outbreak
Valley-Omar [40] 3
Moderate
OS-PC South Africa Hospital
pediatric
Nosocomial outbreak
of H1N1 and children
admitted to pediatric
ward over 4 months
Epidemiology/viral
sequencing
14 cases Nosocomial transmission chains
and infection sources using
phylogenetic analyses
Yes, transmission with HWs,
asymptomatic patients, and
visitors
Melchior [41] 2
Low
Moderate
OS-PC Brazil University
hospital
HIV + patients,
children, contacts,
and HWs
Flu testing in risk groups N = 400 Prevalence of influenza infection
by risk group; influenza
+ asymptomatic; influenza
acquisition by contacts
UC
Dini [11]* 4
High
Moderate
Review Mixed 6 systematic reviews/
28 studies
Influenza Vaccine Not pooled Lab-confirmed flu, ILI,
absenteeism, NNV
Does vaccination in HWs
benefit patients? Yes/No?
UC benefit
Riphagen-
Dalhuisen [25]
4
High
Moderate
cRCT The
Netherlands
Hospital
ward
Internal medicine and
pediatric department
HWs of cRCT
Interventions to increase
uptake
Rates of nosocomial
transmission retrospectively as a
secondary outcome by internal
medicine or pediatric ward
Yes
(continued on next page)
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Table 3 (continued)
Study Maryland
Quality
Score and
classification
Study
Design
Country Setting Included Studies/ or
Population type
Intervention or Focus # of participants Outcomes Do HWs transmit influenza to
patients? Yes/No
Seal [42]* 2
Low
Moderate
Review Mixed 1 systematic review
of systematic reviews
and 2 non-
randomised studies
Influenza vaccine in HWs All-cause mortality, clinically
suspected influenza, vaccine
efficacy, working days lost,
others hospitalization of
patients.
No
Amodio [43] 2
Low
Moderate
CS-RC Italy Hospital Acute care
hospitalized patients
Influenza vaccine in HWs N = 62,343
patients
185 nosocomial
Influenza vaccine coverage,
nosocomial ILI and the
association between the two
Yes
Blanco [44] Can’t score Model USA Hospital Hypothetical hospital
in Michigan
5 influenza preventions 700 patients % reduction of hospitalized flu
cases due to each intervention
Yes assumed
Shugarman [45] 2
Low
Moderate
OB-
survey
USA Nursing
Facilities
Nursing facilities
(nurses = 301)
Influenza vaccine 301 Effect of resident and staff
influenza immunization rates on
the likelihood of ILI clusters.
Yes (ILI)
Dionne [46] 2, Low
Moderate
OS-RCS USA 550 bed
Hospital
Flu + Hospitalized
patients over 5 flu
seasons
Influenza vaccine in HWs 533 influenza
+ nosocomial
cases over 5 years
Proportions of nosocomial cases
among HWs and patients .
Nosocomial influenza rate with
lab-confirmed influenza
confirmation
How many HWs need to be
vaccinated if there is a
benefit?
NNV or range
No association; but some
reduction in up to 50%
vaccine coverage in HWs
Salgado [47] 3, Moderate OS-RCS USA 600 bed
Hospital
Hospitalized patients
in a 600-bed tertiary
hospital over 12 years
Influenza vaccine in HWs N/A Proportions of nosocomial cases
among HWs and patients
Yes, significant proportionate
association between vaccine
coverage in HWs and a
reduction in nosocomial
infections
Van den Dool ‘09
[48]
Can’t score Model The
Netherlands
Simulation of
24 bed ward
hospital
Nursing home model
applied to a general
hospital ward
patients and HWs
Influenza vaccine in HWs N/A Association of HW vaccination
and influenza infections
prevented in patients
Yes, 40% prevention when
100% of HWs vaccinated.
NNV = 3
Van den Dool ’08
[49]
Can’t score Model The
Netherlands
Simulation of
Geriatric
nursing home
Nursing home model
with 30 beds
Influenza vaccination
coverage HWs
N/A Association of HW vaccination
and influenza infections
prevented in patients; herd
immunity
Yes, 60% prevention when
100% of HWs vaccinated.
NNV = 7
Wendelboe 2011
[50]
3
Moderate
CS-PC USA Geriatric,
long-term
care facilities
Residents and HWs of
75 LTCFs with and w/
o outbreaks over two
flu seasons
Vaccination coverage in
HWs
N = 21 lab
confirmed
residents
N = 40 ILI
residents
Odds ratio of outbreak LTCFs by
vaccination coverage of HWs -
Lab-confirmed influenza or ILI
symptoms
Yes, proportionate prevention
of outbreaks with rising
vaccination coverage
Wendelboe 2015
[51]
Can’t score Model USA Geriatric,
long-term
Residents and HWs of
76 LTCFs over one flu
season
Vaccination coverage in
HWs
N/A Herd immunity; HW vaccination
and probability of influenza in
LTCF residents
Yes, Inverse association
*Dini, et al and Seal et al relevant for questions 2&3.
LEGEND: CC– Case Controlled; OS- Observational Study; CS- Cross Sectional; PC- Prospective Cohort; RC- Retrospective Cohort; RCS- Retrospective cross-sectional; SR-Systematic Review; EM- Economic Model; CBA- Cost-Benefit
Analysis; TS- Time Series; RCT- Randomised Controlled Trial ; cRCT- Clustered Randomised Controlled Trial; UC- Unclear; Q1 – Question 1; Q2 – Question 2; Q3- Question 3;RR-Risk Ratio; NNV-number needed to vaccinate.
Maryland Quality Score (2 – 5; Low Moderate – High).
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D.C. Jenkin et al. / Vaccine: X 2 (2019) 100036 9cies remained constant during the study period, but concomitant
increase in patient influenza vaccination rates may have con-
tributed to the decrease in nosocomial infections. A nested-case
control study [75] included in the review by Seal et al. [42] found
that a vaccinated proportion of  35% of HWs in short-stay units
appeared to protect against nosocomial influenza among patients
(OR = 0.07; 95% CI, 0.005–0.98) independent of patient age, influ-
enza season and potential influenza source. The authors concluded
that a minimum of 35% vaccination coverage in HWs would be
required to have a potential protective impact on hospital-
acquired influenza infection.
Dini et al. [11] also included a review by de Serres et al. [73]
who used the mathematical principal of dilution as the basis for
their re-examination of the main 4 cRCTs used as evidence for
mandatory vaccine policies in HW [77–80]. They disputed the
NNV (number needed to vaccinate) of 8 found by Hayward in
2006 in LTCF settings [79] and recalculated it to be 36,000, which
was quickly disputed by Hayward [81]. Hayward stressed that
results from their study in LTCFs were not necessarily applicable
outside of the most frail and vulnerable patients.
In two modelling studies by van den Dool et al. [48,49], one
model in LTCFs predicted ‘‘a robust linear relationship between
the number of HWs vaccinated and the expected number of influ-
enza infections in patients, preventing  60% of influenza virus
infections among patients” (NNV = 7). Comparing these results in
LTCFs to a hospital or short stay setting, they found an equivalent
or higher estimate of impact in hospital patients (NNV = 3) and
that vaccination of 100% of HWs would potentially prevent 40%
of inpatient nosocomially acquired influenza infections.
Topic 3, Question 1– What are the successful and practical inter-
ventions which increase HW influenza vaccine uptake?
We identified several higher quality RCTs and systematic reviews
addressing this question and there is consensus that no single inter-
vention component has been found to rapidly and substantially
raise influenza vaccination rates in HWs, aside frommandatory vac-
cination [82]. However, several systematic reviews [52,59,83] and
tool kits [57,58] have highlighted that multifaceted approaches
which sustain over time can see increases > 90% [47]. Dini et al.
[11] evaluated 7 systematic reviews which together evaluated
strategies to increase uptake in HWs in > 200,000 subjects. They
found that some successful alternatives to mandatory vaccination
included ‘‘soft-mandates”, such as masks, ‘‘opt-out”, or declinations
statements, andmulti-faceted programmes which take into consid-
eration the local context, include incentives, education, advertising,
and easy vaccine access as efforts to enhance behavior change.
Higher level systematic reviews had similar findings including a
meta-regression analysis that [83] found that the single most suc-
cessful strategies after mandatory vaccination were ‘‘soft” mandate
strategies and a policy excluding non-vaccinated HWs from work-
ing with highly vulnerable patient groups. Another systematic
review [52] found that successful interventions contained the fol-
lowing critical components: free and easy access to vaccine;
knowledge and behavior change through educational activities;
reminders and incentives; management/organizational approaches
including personnel charged with implementing the programme;
and a long-term strategy. An additional study of 121 publications
also concluded that all interventions increased uptake to some
extent with the most successful being those which required vacci-
nation as a condition of being allowed to work [84].
Several randomised trials [85] have successfully used a pre-
intervention survey as a basis for subsequent intervention map-
ping [25,86] in the development of multi-faceted interventions.
This is particularly important as the reasons for vaccine hesitancy
are complex and heterogeneous [52], making local, social, cultural,institutional and logistical factors all relevant to the development
of educational or knowledge-based interventions. Other RCTs
failed to dramatically raise uptake using educational tools or man-
uals and a decision aide intervention which changed views but not
actions [54–56].
Topic 3, Question 2 – What are the sociological, behavioural, and
public health policy aspects of influenza vaccine uptake in HWs?
We identified 3 higher moderate studies on this topic, including
two reviews [11,61]. One review [11] evaluated 16 systematic
reviews on vaccination determinants in HWs, adherence to vacci-
nation, and risk perceptions or beliefs about vaccination. The study
broadly found the following: knowledge about influenza varied by
occupation, not necessarily occupational level (doctors vs. dentists
for example); many misconceptions about influenza persist, even
though influenza knowledge has improved over time; the relation-
ship between HWs’ perception and mitigation of risk is complex
and multi-factorial and needs to be better understood. Included
as part of this review was a large systematic review by Schmid
[86] which included 470 studies, of which 117 looked at HW barri-
ers to influenza vaccine uptake. Their review found that micro-level
determinants included age, gender, additional risk factors, and past
behavior as the most reported factors to influence uptake. They fur-
ther evaluated the determinants based on the 4C model for vaccine
hesitancy (complacency, confidence, convenience, and calculation)
and found that the strongest barrier to uptake was a HWs lack of
confidence about disease severity or vaccine effectiveness and ‘‘a
lack of professional or ethical obligation to get vaccinated”. This
was in line with the systematic review by Hollmeyer which found
that HWs are motivated to be immunized against influenza more
often for their own benefit than for the benefit of their patients [52].
Lorenc et al. [61] conducted a systematic review of 25 studies
on HWs’ beliefs and perceptions about vaccination within different
contexts and found that many participants are unsure of the real
value of vaccination programs. This study highlighted that the suc-
cess of a vaccination program may be influenced by the complex
relationship between HWs and the organization and management
of the health care system within which they work. Ofstead and col-
leagues [62] executed a three-part evidence-based intervention
study in LTCFs which compared a multi-faceted ecological model
and the health belief model. They raised uptake from 50% to 85%,
decreased respiratory illness-related absenteeism by 12% and con-
cluded that an ecological model was more effective than the health
belief model at increasing uptake as it includes broader policy or
organizational aspects relevant to program implementation.
4. Discussion
We executed a Rapid Evidence Appraisal [8] of the literature from
2006 to 2018 to evaluate the evidence relevant to the ongoing dis-
cussions about seasonal influenza vaccination in HWs. Influenza
infection and vaccination in HWs poses a complex policy challenge
due to the general lack of high quality evidence, the inherent com-
plexity of influenza, and the number of potential benefactors: HWs
themselves by avoiding influenza infection, their patients by virtue
of reduced influenza transmission in health facilities, their employ-
ers in terms of business continuity, and potentially their families
and wider community contacts.
4.1. Influenza risk to health workers
The evidence on whether HWs are at increased risk of influenza
infection (symptomatic and asymptomatic) in HWs is mixed.
Recent studies suggest a higher risk with pH1N1 [11–13,63], a high
attack rate, and variations in risk which are connected to occupa-
Table 4
Rapid Evidence Appraisal included studies and their characteristics for Topic 3 - Questions 1 & 2.
Study Quality Design # of
participants
or # of
included
studies
Country Population Intervention Question 1 Results
What are the successful and practical interventions which increase
HW influenza vaccine uptake?
Dini 2013 [11] 4
Moderate
High
Review 7 systematic
reviews
Mixed 7 systematic reviews evaluating
> 200,000 subjects
Interventions to
increase uptake in
HWs
Mandatory vaccination is most effective; soft mandates also
effective; multi-faceted, complex/integrated programmes
effective
Riphagen-Dalhuisen 2013 [25] 5
High
cRCT N = 13,830 The
Netherlands
All employees working in 6
University medical centres over
two influenza seasons
Pre-intervention
survey and mode
to develop
intervention
Influenza vaccine coverage significantly higher in intervention
groups (seasonal 32.3% vs. 20.4%; pandemic vaccine 61.7% vs. 38%)
Hollmeyer 2013 [52] 5
High
Systematic
review
24 included
studies
mixed HWs from acute care hospitals
between January 1990-December
2011
Interventions to
increase uptake in
HWs
Increases in vaccine uptake due to free and easy access to vaccine;
education and behavior modification (education, incentives or
reminders); must create culturally-relevant interventions
Abramson 2010 [53] 5
High
cRCT 13 clinics,
163 HCWs
Israel Staff with direct patient contact in
primary care community clinics in
Jerusalem over 2007–2008
influenza season
HMO
recommendation
for vaccination of
HWs
Immunisation rate 52.8% in the intervention group vs. 26.5% in the
control group. Absolute increase since previous year was 25.8% in
intervention clinics vs. 6.6% in the control clinics
Chambers 2015 [54] 4
Moderate
High
RCT Intervention
group = 13,
controls = 13
Canada 26 healthcare organizations across 6
provinces over two flu seasons
A successful
influenza guide vs
nothing new
Intervention improved HW vaccination rates, but these rates
continued to be sub-optimal and below rates achievable in
programs requiring personnel to be immunised
Chambers 2012 [55] 4
Moderate
High
RCT N = 151 Canada Non-vaccinated HWs at 6 weeks of
influenza campaign in a healthcare
centre (hospital, long-term, mental
health)
Ottawa Influenza
Decision Aid
(OIDA)
It appears that the OIDA increases confidence in vaccination
decision but does not increase odds of intending to be immunised
ECDC 2013 [56] 3
Moderate
Review 5 included
studies
European
region
Studies on the drivers and barriers
to influenza vaccination/coverage in
Europe
Interventions to
increase uptake in
HWs
Non-hospital settings: campaigns w/ more components,
education/promotion and improved vaccine access increased
uptake. Only mandatory vaccine could raise uptake above 90%
Europe WHO 2015 [57] Policy
toolkit
Evidence-
based policy
guide/toolkit
36 included
studies
Mixed Guidance on increasing HW
influenza uptake; literature review
Studies of the
determinants of
vaccine uptake
Development of practical guide-Tailoring Immunization
Programmes for Seasonal Influenza (TIP FLU)- categorizes
vaccination decision making by behavioural determinants
(personal, social/community, environmental, contact with HWs)
Europe WHO 2015 [58] 3
Moderate
Review 35 included
studies
Mixed Review to provide examples to
countries of successful and
replicable interventions to increase
uptake in HWs
Interventions to
increase uptake in
HWs
Most successful interventions include multiple components;
important to increase demand through changes in policy,
legislation, and legislation; HWs need burden and risk data
Macdonald 2013 [59] 4
High
Moderate
Systematic
literature
review
22 included
evaluations
European
region
Review of 22 evaluation studies in
Europe of promotional
communication interventions
Promotional
communications
for flu in Europe
They found that all forms of communication can stimulate HW
vaccine uptake; promotional communications that target HWs can
also improve uptake among patients
Stuart 2012 [60] 4
High
Moderate
Review 11 included
studies
Australia 11 studies on seasonal influenza
uptake rates of Australian HWs,
determinants and strategies to
increase uptake
Interventions to
increase uptake in
HWs/
determinants
Factors contributing to immunisation in Australia show only
minor variations from international samples. Not enough quality
evidence on effective strategies in Australian and globally
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D.C. Jenkin et al. / Vaccine: X 2 (2019) 100036 11tional exposure. Other studies find a risk to patients and HWs dur-
ing an outbreak [16] and following contact with ILI patients [15].
Additional studies suggest only a risk of asymptomatic infection
[17,64]. Taken together, these studies highlight that setting [88],
occupation [89] or patient contact level, risk procedure [90], circu-
lating virus, and existing immunity in the population (i.e. H1N1)
can all vary risk [63]. However, respiratory illness has been
reported as one of the main causes of sickness absence in HWs
[92,91], pandemics and epidemics can be associated with concur-
rent increased rates of HW absenteeism [12,92,93], and HWs do
overall appear to be at risk of contracting influenza.
4.2. Vaccine benefit to health workers or their employers
Recent higher level evidence [11,18] evaluating RCTs, cohort
studies, and systematic reviews does suggest a vaccine benefit to
HWs and their employers including a protective effect against
laboratory-confirmed influenza, shortened sick leave, and a
reduced incidence of absenteeism (due to ILI). However, vaccine
benefit studies during the years of pH1N1, including an RCT in
the Netherlands, found the opposite effect, an increase in absen-
teeism in the vaccination arms. Different authors draw contradic-
tory conclusions from the use of the same RCTs [94–96],
indicating a need for updated, large scale studies of higher quality.
Observational studies also draw different conclusions and are con-
strained by poor study design, non-specific outcomes, a high risk of
bias, and failure to adjust for confounding factors. Absence due to
ILI is frequently used as an outcome measure when ILI itself has
relatively poor predictive value for influenza infection [97,98].
Although studies may provide contradictory conclusions, vaccine
efficacy in HWs has been shown to be as high as 90% for well-
matched seasonal influenza vaccines [66,68], and high for pan-
demic vaccine [99]. Therefore, it seems reasonable that vaccinating
HWs against influenza will reduce influenza burden in HWs,
related work absenteeism, and possibly influence subclinical infec-
tion and/or ‘‘presenteeism” – attending work whilst ill.
4.3. Influenza risk to patients
The expanding volume of studies combining epidemiological
and phylogenetic analysis, among other new technologies
[71,72], suggest that HWs are implicated in at least some transmis-
sion during nosocomial outbreaks of influenza. However, the com-
plexity of transmission in health facilities is also driven by various
factors including patient to patient and visitor to patient contact,
varying levels of possible infectiousness with asymptomatic vs.
symptomatic transmission, and high patient turnover, particularly
in acute care settings [37,38,40]. Nevertheless, Pagani et al. [35]
identified multiple introductions of strains into the hospital from
the community during an outbreak and noted that unvaccinated
HWs may have played an important role in sustaining the out-
break. Other factors which may increase or decrease the extent
to which HWs are implicated in transmission are individual
(immune status, severity of disease, viral shedding), pathogen (vir-
ulence, infective dose), and environmental factors (infection con-
trol practices, ward layout, frequency of patient, staff and visitor
contacts), including contact with HWs of varying degrees of risk
exposure themselves. Notwithstanding, the evidence does suggest
that HWs can clearly pose a transmission risk to patients, at least
some of the time.
4.4. Vaccine benefit to patients
The benefit of HW influenza vaccination to patients is not clear
or consistent in the literature and continues to be debated as
numerous systematic reviews using mostly the same RCTs [77–
Table 5
Rapid Evidence Appraisal summary of findings table for all questions.
Review Question # of
individual
studies
included
by
question
# of Higher Quality
studies (Maryland
Quality Score  4)
Settings Populations or#
of studies included
Main findings Limitations of included studies Future Considerations
Topic 1
Question 1
Are HWs at an
increased risk of
influenza infection?
7 1 study
A Comprehensive
review which
evaluates systematic
reviews addressing
this question.
-Hospital settings with
different occupations such
as physicians, nurses,
close patient contact or
less patient
-H1N1 risk and Seasonal
influenza risk
-Patients and HWs during
outbreaks
-Yes, in some cases, HWs are at an
increased risk, but not always
-H1N1pdm09 risk to HWs is clearer than
seasonal influenza
-Risk can vary by occupation with
H1N1pdm09 but unclear for seasonal
influenza
-Influenza risk appears to vary year to year
depending on virus circulation
–Difficult to look across multiple studies to
draw conclusions unless controlling for study
year, circulating virus, patient populations,
health worker type or occupation
–Pooled data may lead to inaccurate
conclusions
-Publication and selection Bias
-Use of indirect measures of influenza
-Use of seasonal influenza elements for
pandemic models
-Research to validate variability
in risk with influenza by year,
virus, occupation, setting,
patient populations
- Consideration of this
variability in risk as an inherent
part of research or policy
development
Topic 1
Question 2
Does influenza
vaccination benefit
HWs or their
employers?
14 4 studies
2 reviews,
2 RCTs
-Hospital settings
-University medical
centres
-Staff and students of
Dental Faculty
-Trivalent vaccine
-H1N1pdm09 vaccine
-Yes, vaccine can be cost-saving and reduce
influenza burden, but it isn’t entirely
consistent
-Several higher-level studies suggest vaccine
efficacy in health workers and cost-savings to
employers through reduced absenteeism
-We identified a total of 5 RCTs to answer this
question, 2 not part of recent systematic
reviews and had conflicting results
-One RCT during 2009–2011 found
vaccination to increase absenteeism
-One RCT only used ILI as an outcome
measure
-Vaccine benefit may be greater when
considering asymptomatic influenza and the
possible impact on transmission
-Applying vaccine effectiveness, efficacy,
or attack rate of healthy adults to HWs.
-Self-reported outcomes
-Non-specific outcomes
-low circulation of virus confounds
vaccine effectiveness
-A need for updated high quality
RCTs assessing vaccine benefit
over time in multiple settings.
–Develop research standards for
influenza vaccine benefit
–Vaccine type may vary findings
Topic 2
Question 1
Do HWs transmit
influenza to patients?
11 1 study
Using high
resolution contact
data detected with
sensors
-Patients and HWs in
Elderly care Hospital
Wards
-In HIV + patients, –In
children
During Nosocomial
outbreaks
-Yes, HWs have been implicated in some
transmission events, most frequently
among elderly patients
-Transmission and introduction can be
directly linked to HWs, patients, and
community/visitors-
-Small sample size in many studies
-Most studies of moderate quality
-Need to better understand the
role of asymptomatic infections
in transmission
-Transmission reduction
measures need to consider HWs,
patients, and outside contacts as
a continuum
-Need larger studies over a
longer duration using high-
resolution contact data
Topic 2
Question 2 Part A
Does influenza
vaccination in HWs
benefit patients
6 2 -Long-term care facilities
in patients -Acute Care
facilities
-Internal Medicine
-Pediatrics
-Maybe - evidence continues to suggest a
benefit on protection against all-cause
mortality to LTCF patients
-Evidence is mixed in other populations, but
one RCT in the Netherlands suggests a
reduction in nosocomial infection in internal
medicine wards, not pediatrics
-Very few newer RCTs evaluating patient
benefit
-Several studies evaluate ILI rather than lab-
confirmed as a measure of benefit
-Decisions based on 4 highly biased RCTs
in long-term care facilities due to
attrition rate, no blinding, contamination
in control groups, low rates of
vaccination coverage
-Need updated cRCTs which
span years
-Need standardized approaches/
population to answering this
question
-Patient benefit variations need
to be understood and
appreciated (more benefit to
more vulnerable patients)
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Table 5 (continued)
Review Question # of
individual
studies
included
by
question
# of Higher Quality
studies (Maryland
Quality Score  4)
Settings Populations or#
of studies included
Main findings Limitations of included studies Future Considerations
Topic 2
question 2 Part B
How many HWs need to
be vaccinated (NNV) to
ensure a benefit to
patients?
6 0 -Long term care facilities
-Medical Centre hospital
-Tertiary Hospital
-NNV range from 3 to 50
-Appears to be a benefit in LTCFs when 100%
of HWs are vaccinated with the possible
prevention of 60% of infections
-Appears to be a proportional benefit with a
greater reduction in nosocomial transmission
with higher coverage
-Appears to be a curvilinear relationship
between rising coverage and reduction in
nosocomial infections that can be impacted
by visitors or other contact elements
-Vaccine effectiveness for HWs based on
that for healthy adults
-Other assumptions in models may lead
to inaccurate conclusions
-Outcome definitions in models
significantly impacted whether herd
immunity could be induced
-NNV estimates need to factor in
differences in outcome
measures used
-Need to expand body of
knowledge beyond geriatric
populations which may skew
the total findings
-Need to develop HW vaccine
efficacy and attack rate
standards for models
Topic 3
Question 1
What are the successful
and practical
interventions which
increase HW influenza
vaccine uptake?
10 8 -Primary care community
clinics
-Acute care hospital staff
-HWs in tertiary hospitals
-HWs with and w/o
patient contact
-All personnel of a health
institution
-Mandatory Vaccination to be able to work
remains the most successful intervention
to increase uptake
-Other successful interventions are:
 Multi-faceted including many elements
together (the more the better)
 Sustain over time
 Provide free and easy access to vaccine
 Use behavior change components (remin-
ders, incentives, education)
 Develop targeted multi-faceted interven-
tions using baseline data collection to
identify barriers in that population
 Vaccine promotion from highest levels
 Having a vaccine organizer from inside
 Opt-out programs (declination state-
ments, required mask use, flu-safe
zones)-Appears that intervention success
is linked in some respects to the number
of interventions
Publication bias considering studies that
were not effective may not be published
-Selection bias as some may not have
reported baseline vaccine uptake before
intervention
-Lack of blinding in RCTs
-Hard to separate the benefit of one
intervention as distinct from the others
when a part of multi-faceted
interventions
-Clear guidance needed on
vaccine program
implementation in HWs which
clarify the options of mandatory
policy options vs. other.
-Develop a standardized
checklist of components critical
for vaccine uptake success
- Develop guidance on how to
develop targeted interventions
catering to the individual
context for implementation
Topic 3
Question 2
What are the
sociological,
behavioural, and public
health policy aspects of
influenza vaccine
uptake in HWs?
3 3 -Long-term care facilities
- Mixed hospital settings
of HWs
-Mixed outpatient
settings of HWs
-Strongest barriers to uptake were HW’s
lack of confidence about disease severity or
vaccine effectiveness and a lack of
professional or ethical obligation to get
vaccinated.
-Strongest reason to vaccinate was to protect
oneself and not patients
-Success of a vaccination program may be
influenced by the complex relationship
between HWs and the organization and
management of the health care system
within which they work.
-Ecological model shows promise an
alternate to the widely used health belief
model
-Limited use of models other than Health
Beliefs Model
-Greater diversity of study
approaches to reframe issues
through alternative lenses
-Need to integrate HW influenza
vaccine programs into existing
programs to ensure long term
-Need to expand discussion on
the importance of top-down
support for vaccine programs in
HWs to develop a culture of
vaccination
-Need to have a better
understanding of the influenza
of management /organizationl
structures where
implementation will take place
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Fig. 1. Flow Diagram of the literature search strategy, study removal and selection by topic.
14 D.C. Jenkin et al. / Vaccine: X 2 (2019) 10003680] all draw different conclusions [11,66,73,76]. Research in LTCFs
has consistently shown a benefit to patients, at least for all-cause
mortality. Variations across study populations or studies, such as
patient populations, level of HW to patient contact, patient vulner-
ability or susceptibility, or levels of risk exposure for HWs them-
selves, limit comparability between findings. This may explain
why studies in LTCFs consistently find vaccination of HWs benefi-
cial to elderly patients, where the stability of the setting, patient
characteristics, and high level of contact between HWs and
patients are all consistent factors. Whereas, a larger body of evi-
dence suggests an unclear association between HW vaccination
and patient benefit in hospital settings, which may be due to vari-
ations in study design, HW or patient characteristics, their individ-
ual risk or susceptibility, difference in vaccine type or diagnostic
testing, or even the time of year. LTCF patients do however appear
to benefit, at least regarding mortality, which demonstrates that
vaccine benefit to patient warrants efforts to increase vaccination
in HWs caring for the elderly [100].
4.5. Influenza vaccine uptake
The factors that feed into a HWs decision-making pathway for
influenza vaccination are diverse and individually-driven [52].
Therefore, any efforts must be as equally diverse as the HWs they
target. Mandatory vaccination is debated extensively from many
perspectives including the reasons for [21] and against it [73];
however, no amount of debate can refute that mandatory vaccine
policies do raise uptake quickly, usually to levels in excess of 94–
96% [82]. Other successful interventions are multi-faceted, sus-
tained over time [47], and evolve over time as data is collected
on the target population [85]. These make vaccine easily accessible,
maintain strong organizational support, develop education which
varies by targeted groups, and may include ‘‘soft-mandate” poli-
cies, such as declination statements, or alternatives such as masks
[52,83].
One area which deserves more consideration, is the use of dif-
ferent types of models in the development of interventions to
improve uptake. Traditionally, the health belief model is most
commonly used. However, studies exploring other possibilities
[62,86] have shown promise with an ecological model, which takes
into consideration the contextual, organizational, policy or back-
ground components which are relevant to a vaccine program andhenceforth to a HWs decision to take the vaccine. These models
incorporate the growing understanding that HW vaccine uptake
involves much more than individual knowledge, attitudes, and
beliefs. The greater context of the HW and their relationship to
the organization, other HWs, and broader cultural factors are all
important to vaccine uptake.
4.6. Study limitations
Although we made every effort to execute an unbiased and sys-
tematic approach to our search and selection of included literature,
our study was not without limitations. Due to resource and time
constraints, we limited the search to English language abstract or
full-text articles, did not include grey literature, and removed pub-
lications that were included as part of a more recent systematic
review. This may have led to some selection bias and limited our
exposure to all relevant articles. However, due to the breadth of
questions included in the search and the execution of three distinct
searches, we felt that this diversification may have added strength
to the study design to compensate for this weakness.
The majority of included studies were observational studies,
which limits the strength of our findings as observational studies
are susceptible to bias and there is limited ability to infer causality.
Additionally, many studies were executed in different types of set-
tings, with different target populations, using different vaccines
and with varying levels of risk or exposure to the populations being
studies. This makes comparing across studies very difficult.
Our methodology lacks the robustness of a formal systematic
review ormeta-analysis and does not report on effect size. System-
atic reviews have very defined limitations for study selection and
inclusion and typically do not query so many questions. We exe-
cuted a Rapid Evidence Appraisal - a time-limited effort of assess-
ing the evidence to draw conclusions, a process similar to what
might happen in a ‘real-life’ policy environment. To compensate,
we approached the literature search in a systematic way to add
robustness to our study design and the breadth of our included
questions and consideration of multiple elements relevant to the
decision-making process, offers a more realistic approach for pol-
icy makers. Finally, our study was adapted and updated from a
white paper originally intended to advise and inform WHO when
establishing the influenza vaccine research agenda. The objective
was to support global policy recommendations.
(A)
(B)
Fig. 2. (A and B). % Distribution of different study types included in our review and % distribution of included studies by Maryland Scientific Methods Quality Scale. (A) %
Distribution of Included Study Types by Topic and Question illustrates the limited number of randomized-controlled trials. (B.) % Distribution of Included Studies by Maryland
Scientific Methods Quality Scale illustrates the limited number of high-quality studies identified.
D.C. Jenkin et al. / Vaccine: X 2 (2019) 100036 155. Conclusion (see summary of findings Table 5)
In recent years, several comprehensive reviews
[11,18,42,61,64,66,67,73,74,76,83,86,87] have attempted to rigor-
ously address different aspects of influenza vaccination in health
workers. Paradoxically, the number of reviews far outweighs the
number of studies that are of high quality or give definitive
answers. Similarly, our review included only RCTs that have not
already been evaluated as part of a more updated systematic
review. It is therefore hardly surprising that it has proved difficult
to draw universal and emphatic conclusions for policy makers,
government leaders, and healthcare managers; and that imple-
mentation is poor and acceptance low.
Nevertheless:
 Nosocomial influenza is a recognized problem and it is clear
there is a problem to solve or a case to answer. There is adequate evidence that HWs contract influenza and
data suggests they are at risk of continuing to work whilst
infected.
 There are sufficient data to conclude that influenza vaccines are
as effective in HWs as in other adults of similar age.
 Data are emerging that capture the complexity of influenza
transmission in health facilities and new molecular evidence
implicates HWs in transmission events.
 Data on whether vaccinating HWs protects patients is of mixed
quality and does not universally favor a positive (protective)
outcome. However, there are strong signals from studies in
LTCFs that HW vaccination protects patients, especially with
regard to mortality.
The evidence base requires improvement and future research
should aim to evaluate the impact of HW vaccination on clearly
defined and standardized outcome measures in specific cohorts
16 D.C. Jenkin et al. / Vaccine: X 2 (2019) 100036of beneficiaries. A better understanding of transmission dynamics
across a diversity of HW and patient risk groups is needed to facil-
itate a more nuanced and useful estimation of the wider benefits of
HW influenza vaccination. The large body of knowledge on effec-
tive ways to increase vaccine uptake in HWs needs to be incorpo-
rated consistently within vaccination policies and practices.
Programmes will need to consider the importance of organiza-
tional and contextual factors as drivers alongside the individual
perceptions of HWs. The evidence demonstrating the effectiveness
of mandation in improving uptake is however emphatic.
Influenza is likely to persist as a unique methodological chal-
lenge for researchers to produce reliable and robust results which
lead to definitive conclusions about HW vaccination. Influenza bur-
den, infectiousness, and severity vary yearly, seasonally, and spa-
tially. Influenza risk also varies by setting, such as in proximity
to young children or immune-compromised individuals, and by
occupation or activity (such as performing respiratory procedures
on infected patients). Additionally, influenza vaccine effectiveness
is equally variable by season and subtype, making comparisons
between years and populations challenging.
Due to the inherent complexity of influenza, waiting for the per-
fect results with influenza risks decision paralysis. When consider-
ing the evidence with a ‘whole-of-system’ approach, rather than
considering specific evidence questions in isolation, we argue that
the case for vaccinating HWs against influenza is maintained. Fur-
thermore, to ensure the success and likelihood of expansion of sea-
sonal influenza programs globally, guidance is needed for policy
makers and implementers on how to best integrate influenza vac-
cination to HWs within existing vaccination and occupational
health frameworks.
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